Home » Stocks » GKOS

Glaukos Corporation (GKOS)

Stock Price: $71.79 USD 2.25 (3.23%)
Updated December 3, 2:23 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 3.23B
Revenue (ttm) 217.57M
Net Income (ttm) -73.12M
Shares Out 44.71M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $71.79
Previous Close $69.54
Change ($) 2.25
Change (%) 3.23%
Day's Open 69.45
Day's Range 69.45 - 71.96
Day's Volume 177,651
52-Week Range 25.53 - 71.96

More Stats

Market Cap 3.23B
Enterprise Value 3.10B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 44.71M
Float n/a
EPS (basic) -1.50
EPS (diluted) -1.70
FCF / Share -0.98
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.99M
Short Ratio 8.33
Short % of Float n/a
Beta 1.87
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 14.83
PB Ratio 4.49
Revenue 217.57M
Operating Income -141.86M
Net Income -73.12M
Free Cash Flow -43.77M
Net Cash 131.65M
Net Cash / Share 2.93
Gross Margin 93.02%
Operating Margin -65.20%
Profit Margin -33.60%
FCF Margin -20.12%
ROA -7.40%
ROE -17.17%
ROIC -31.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (10)

Buy 3
Overweight 0
Hold 4
Underweight 1
Sell 2

Analyst Consensus: Overweight

Price Target

$55.89*
(-22.14% downside)
Low
48.0
Current: $71.79
High
70.0
Target: 55.89
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue23718115911471.7045.5920.95
Revenue Growth30.73%13.83%39.21%59.55%57.28%117.64%-
Gross Profit19815613898.2258.7134.1718.41
Operating Income-50.29-13.00-2.284.24-10.30-13.17-14.20
Net Income15.42-12.95-0.094.52-37.24-12.13-12.64
Shares Outstanding37.3635.3234.3832.9317.472.292.04
Earnings Per Share0.37-0.37-0.12-2.13-5.29-6.21
Operating Cash Flow-0.3718.8626.0912.31-2.19-7.11-13.31
Capital Expenditures-4.72-10.32-6.31-6.28-0.88-0.87-0.85
Free Cash Flow-5.098.5519.786.03-3.07-7.98-14.16
Cash & Equivalents18314911995.8491.202.366.79
Total Debt72.63---9.7019.3517.50
Net Cash / Debt11114911995.8481.51-16.99-10.71
Assets81820716613411726.0230.88
Liabilities14533.1127.6317.1021.4729.5523.71
Book Value67317413811795.19-151-141
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Glaukos Corporation
Country United States
Employees 600
CEO Thomas Burns

Stock Information

Ticker Symbol GKOS
Stock Exchange NYSE
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NYSE: GKOS
IPO Date June 25, 2015

Description

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; iDose Travoprost, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication; and MicroShunt, an ab-externo device for treatment of open-angle glaucoma. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.